Obrixtamig Plus Chemotherapy for Advanced Neuroendocrine Cancer

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Recruiting Phase 3 Interventional Study
Extrapulmonary Neuroendocrine Cancer (epNEC)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
390 (estimated)
Sponsor
Boehringer Ingelheim · Industry
Who this trial is looking for

This trial is looking for adults with advanced extrapulmonary neuroendocrine cancer. Participants will receive a study medicine called obrixtamig along with standard chemotherapy and will be monitored for their health over time.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with advanced extrapulmonary neuroendocrine cancer.
  • I am at least 18 years old.
  • I have not received prior systemic treatment for my cancer.
  • I have finished one cycle of platinum plus etoposide chemotherapy.
  • I have adequate tumour tissue available for testing.
  • I have an ECOG score of 0 or 1.

You may not be able to join if

  • I have leptomeningeal disease or carcinomatous meningitis.
  • I have Merkel cell carcinoma or medullary thyroid carcinoma.
  • I have neuroendocrine prostate cancer.
  • I have well-differentiated neuroendocrine tumours.
  • I have previously been treated with obrixtamig or other DLL3-targeting therapies.
  • I have experienced unresolved toxicity from previous treatments.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patients with poorly differentiated unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinoma (epNEC) with Ki-67 \>20% or mitotic rate mitotic rate with number of mitoses \>20 per 2 mm2, regardless of primary site (including site of unknown origin) 2…
Contacts

Boehringer Ingelheim

1-800-243-012

clintriage.rdg@boehringer-ingelheim.com

CONTACT